Latest Beta-secretase 1 Stories
Researchers at the Department of Psychiatry and Psychotherapy of the University Medical Center of Johannes Gutenberg University Mainz (JGU) have recently gained new insights into treating Alzheimer's disease.
Phase II/III trial of AZD3293, an oral potent small molecule inhibitor of BACE, aims to enroll more than 1,500 patients in 15 countries INDIANAPOLIS, Dec.
-Discovery of Novel Investigational Drug Candidates that Interact with sigma-2/PGRMC1 Receptor Offer Potential to Stop and Reverse Memory Loss in Alzheimer's Patients - PITTSBURGH,
Two drugs to be studied in North America and Europe in volunteers at high risk for disease COPENHAGEN, Denmark, July 15, 2014 /PRNewswire/ -- Researchers from the Banner Alzheimer's
Study Results Presented at the Alzheimer's Association International Conference 2014 INDIANAPOLIS, July 13, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results
Highlights include additional analyses from Phase 3 and ongoing open-label studies, discovery research on the potential use of combination therapy and data on the impact of beta-amyloid imaging on
MetLife Foundation has announced the recipients of the 2014 MetLife Foundation Awards for Medical Research: Riqiang Yan, Ph.D., vice chair of the Department of Neurosciences, Lerner Research
Harvard stem cell scientists have successfully converted skins cells from patients with early-onset Alzheimer's into the types of neurons that are affected by the disease, making it possible for the first time to study this leading form of dementia in living human cells.
- Milestone achieved for BI's initiation of Phase 1 study in beta-secretase (BACE) inhibitor program FORT WASHINGTON, Pa., Feb.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.